# US 2008/0312145 A1 · Agent for Regulating Bone Formation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0312145 A1
- Document ID: US20080312145A1
- Status: Published application
- Kind: A1
- Application number: 11/721,834
- Filed: 2005-12-15
- Published: 2008-12-18
- Earliest claimed: 2004-12-16
- Assignees: AnGes MG, Inc.
- Inventors: Hideo Shimizu; Hironori Nakagami; Ryuichi Morishita
- Web page: https://patentgrep.com/patent/US20080312145A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C12N 2310/13: Decoys
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled by using a decoy of the present invention to inhibit NF-κB, a transcriptional regulatory factor that regulates osteoclast differentiation. This method uses a mechanism different from those of previous pharmaceutical agents; therefore, one can expect it to be effective for cases in which existing pharmaceutical agents were not effective.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A method for modulating bone formation, comprising administering a pharmaceutical composition comprising a bone formation-related transcriptional regulatory factor binding sequence, wherein the sequence is selected from the group consisting of a decoy, an antisense, a ribozyme, an aptamer, and an siRNA.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The method of claim 28, wherein the comprises a DNA or an RNA.

### Claim 31 (depends on 30)

The method of claim 30, wherein the decoy comprises a DNA oligonucleotide.

### Claim 32 (depends on 28, 30, 31)

The method of any one of claims 28, 30 and 31, wherein the decoy is a decoy of NF-κB, STAT-1, STAT-3, STAT-6, Ets, AP-1, E2F, Smad1, Smad2, Smad3, Smad4, Smad5, Smad6, Smad7, Smad8, or Runx2/Cbfa1.

### Claim 33 (depends on 32)

The method of claim 32, wherein the decoy is a decoy of NF-κB, and comprises the NF-κB binding sequence GGGRHTYYHC, wherein R comprises A or G, Y comprises C or t, and H comprises A, C or T.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The method of claim 33, wherein the decoy comprises the NF-κB binding sequence of SEQ ID NO: 2, SEQ ID NO: 23 or SEQ ID NO: 24.

### Claim at position 10

36-37. (canceled)

### Claim 38 (depends on 32)

The method of claim 32, wherein the decoy comprises the STAT-1 or STAT-3 binding sequence TTCCGGGAA.

### Claim 39

(canceled)

### Claim 40 (depends on 32)

The method of claim 32, wherein the decoy comprises the STAT-6 binding sequence TTCCCAAGAA.

### Claim 41

(canceled)

### Claim 42 (depends on 32)

The method of claim 32, wherein the decoy comprises the Ets binding sequence CGGAA.

### Claim 43

(canceled)

### Claim 44 (depends on 32)

The method of claim 32, wherein the decoy comprises the AP-1 binding sequence TGAGTCA.

### Claim 45

(canceled)

### Claim 46 (depends on 32)

The method of claim 32, wherein the decoy comprises the E2F binding sequence TTTCCCGC.

### Claim 47 (depends on 32)

The method of claim 32, wherein the decoy comprises the Smad1, Smad2, Smad3, Smad4, Smad5, Smad6, Smad7, or Smad8 binding sequence GTCT, CAGA, GCCG, GTCTAGAC or CAGACA.

### Claim 48

(canceled)

### Claim 49 (depends on 32)

The method of claim 32, wherein the decoy comprises the Runx2/Cbfa1 binding sequence ACCACA or AACCACA.

### Claim 50

(canceled)

### Claim 51 (depends on 28, 30)

The method of claim 28 or 30, wherein the decoy comprises a double-stranded DNA.

### Claim 52 (depends on 28)

The method of claim 28, wherein the modulation prevents ameliorates, or treats a disease caused by a disturbed balance between osteoclasts and osteoblasts.

### Claim 53 (depends on 52)

The method of claim 52, wherein the disease is selected from the group consisting of osteoporosis, Paget's disease, bone tumor, traumatic chondral defect, osteochondritis dissecans, osteoarthritis, rheumatoid arthritis, bone fracture, dislocation, periodontal disease, and dental caries.

### Claim 54 (depends on 28)

The method of claim 28, wherein the modulation ameliorates an orthodontic or artificial dental implant treatment.

### Claim at position 28

55-81. (canceled)

### Claim 82 (depends on 28)

The method of claim 28, wherein the pharmaceutical composition is administered locally, systemically, orally, or parenterally.

### Claim 83 (depends on 28, 82)

The method of claim 28 or 82, wherein the pharmaceutical composition is administered to an adult in an amount from 10 nmol to 10,000 nmol per day, wherein the amount is administered either at a single site or divided in multiple sites.

### Claim 84 (depends on 28, 82)

The method of claim 28 or 82, wherein the pharmaceutical composition is administered alone or with a carrier.
